Black Diamond Therapeutics Inc. (NASDAQ:BDTX) concluded the trading at $4.24 on Friday, January 14 with a fall of -1.40% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $4.30 with its price kept floating in the range of $3.99 and $4.29 on the day. Considering stock’s 52-week price range provides that BDTX hit a high price of $30.71 and saw its price falling to a low level of $4.26 during that period. Over a period of past 1-month, stock came subtracting -20.15% in its value.
With its current market valuation of $150.31 million, Black Diamond Therapeutics Inc. is set to declare its quarterly results on Mar 23, 2022 – Mar 28, 2022. Analysts are in estimates of -$1.01 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$3.76 for 2021 with estimates of that growing to -$3.98 in next year. These estimates are suggesting current year growth of -83.40% for EPS and -5.90% growth next year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review BDTX stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 7 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 1 of them are recommending Black Diamond Therapeutics Inc. (BDTX) as a Hold, while 6 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the BDTX stock which is currently positioned at 0. It further provides that stock’s current price level is -18.00% away from its 20-day simple moving average and is -31.34% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 33.28 while volatility remained at 10.77% over the past week which changes to 8.39% when measuring it over the past month. Average true range or ATR is currently at 0.44. In predicting price targets of as low as $10.00 and as high as $53.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $27.83. Stock’s current price level is -135.85% above from estimated low price target while it is -1150.0% below the estimated high; and even if the BDTX’s share succeeded to reach the median price of $27.50, then the outlook of -548.58% could come to the excitement of the investors.
Having a second look at Black Diamond Therapeutics Inc. (NASDAQ:BDTX) provides that stock’s average daily trading volume for 3 months was 551.01K. Number of outstanding shares of the stock stood at 36.22 million.
The percentage of outstanding shares held by the insiders is 0.40% while it is 85.20% for the institutional holders. Subtraction of -20.45% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.